AllergyTalk
AllergyTalk delivers the latest insights and evidence shaping allergy and immunology. In each bimonthly episode, leading experts break down the most impactful research and real-world takeaways from AllergyWatch®, a bimonthly publication summarizing key findings from 20 major journals in allergy and asthma.
Episodes
Oct 2, 2019
Oct 2, 2019
36 min
For today’s episode we will be reviewing three articles from the July-August 2019 issue of Allergy Watch:
Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis
https://www.ncbi.nlm.nih.gov/pubmed/30488542
Allergen content in German cockroach extracts and sensitization profiles to a new expanded set of cockroach allergens determine in vitro extract potency for IgE reactivity
https://www.ncbi.nlm.nih.gov/pubmed/30170124
New IgE immediate hypersensitivity reactions on reintroduction of food restricted for treatment of eosinophilic esophagitis
https://www.ncbi.nlm.nih.gov/pubmed/30684739
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee was on an advisory board for Teva.
Dr. Kalangara has received consulting fees from AstraZeneca.
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
Jul 23, 2019
Jul 23, 2019
28 min
For today’s episode we will be reviewing three articles about food allergy and eczema from the May-June 2019 issue of Allergy Watch:
The Basophil Activation Test reduces the need for a food challenge test in children suspected of IgE-mediated cow's milk allergy.https://www.ncbi.nlm.nih.gov/pubmed/30408255
Oral food challenge failures among foods restricted because of atopic dermatitis.https://www.ncbi.nlm.nih.gov/pubmed/30326323
The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype.https://www.ncbi.nlm.nih.gov/pubmed/30787169
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee was on an advisory board for Teva.
Dr. Kalangara has received consulting fees from Astra Zenica.
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, ShireResearch: Aimmune, DBV, Shire, Regeneron.
Jul 23, 2019
Jul 23, 2019
37 min
For today’s episode we will be reviewing three articles about asthma from the May-June 2019 issue of Allergy Watch:
Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.https://www.ncbi.nlm.nih.gov/pubmed/30217529
Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.https://www.ncbi.nlm.nih.gov/pubmed/30205189
Indirect Treatment Comparisons and Biologicshttps://www.ncbi.nlm.nih.gov/pubmed/30612667
Endotypes of severe allergic asthma patients who clinically benefit from anti?IgE therapyhttps://www.ncbi.nlm.nih.gov/pubmed/30107059/
Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthmahttps://www.ncbi.nlm.nih.gov/pubmed/29301922
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee was on an advisory board for Teva.
Dr. Kalangara has received consulting fees from Astra Zenica.
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, ShireResearch: Aimmune, DBV, Shire, Regeneron.
May 15, 2019
May 15, 2019
47 min
With guest Stanley Fineman, MD, MBA, FACAAI, editor-in-chief of AllergyWatch.